As a neurodegenerative disorder, Alzheimer disease (AD) is the most common form of dementia found in the aging population. Immunotherapy with passive or active immunizations targeting amyloid beta (Aβ) build-up in the brain may provide a possible treatment option and may help prevent AD from progressing. A number of passive immunizations with anti-Aβ42 antibodies are in different phases of clinical trials. One active immunization approach, AN-1792, was stopped after the development of autoimmune encephalitis in 6% of patients and a second one, CAD106, in which a small Aβ epitope is used, is currently in safety and tolerability studies. Besides active immunizations with proteins or peptides, active immunizations using DNA which codes for the protein against which the immune response will be directed, so called genetic immunizations, provide additional safety as the immune response in DNA immunizations differs quantitatively and qualitatively from the response elicited by peptide immunizations. We summarize in this review our data using DNA Aβ42 immunizations in mouse models and discuss the results together with the results presented by many other groups working on a DNA vaccine as treatment option for AD.
the development of neurofibrillary tangles [1, 2] . Twenty years ago the amyloid cascade hypothesis was formulated, which postulated that Aβ deposition is the initial event in the multifactoral pathogenesis of AD [3] [4] [5] . There is significant evidence that Aβ peptides play a major role in the onset and progression of AD [6, 7] . Important findings showing that Aβ42 may not only serve as a marker, but may contribute to the development of AD came from a genetic study in Iceland. In this study, a single mutation (A673T) within the amyloid precursor protein (APP) gene resulted in a 40% reduction of the β-secretase cleavage product of APP: Aβ1-42; and carriers of this rare mutation were protected against developing AD [8] .
Outcomes from a recently approved clinical trial to prevent AD will provide important information whether the amyloid hypothesis is valid in this regard. In this study, cognitively healthy patients who carry a presenilin-1 (PSEN1) genetic mutation and are highly likely to develop AD at around 45 years of age will be passively vaccinated with a humanized monoclonal antibody (Crenezumab). The antibody will bind to Aβ42 and likely interfere with formation of amyloid plaques and thus disease progression (New York Times, May 15, 2012, and [9] were attributed to the antibodies only [24, 25] .
A new study using active Aβ immunization in Swedish AD patients has recently been published [26] . This vaccine, CAD106, consists of a B cell epitope peptide, Aβ1-6, which is coupled to a carrier protein displaying a second protein, 180 copies of a bacteriophage coat protein, to provide T cell help for the anticipated immune response. This study was performed to provide safety, tolerability, and antibody responses to this particular vaccine, and the outcome showed a positive antibody response in most patients and no signs for adverse autoimmune inflammation were noted. Data from this study are limited and longer lasting studies with more patients are needed but due to the lack of negative side effects this study will progress into a phase 2 study and is ongoing [26] .
mechanisms of how Aβ42 specific antibodies lower the amyloid burden in brain
The answer to this very important topic can be addressed only hypothetically as it has not been shown which mechanism is predominantly used, and there will likely be more than one which is used. In general, it is Constitutive expression of the GAL4 transcription factor is driven by a cytomegalovirus (CMV) promoter on the activator plasmid. The GAL4 protein binds as a homodimer to the responder plasmid at sites in the upstream activator sequence (UAS), as part of a minimal promoter. GAL4 binding drives transcription of the β-amyloid1-42 (Aβ42) trimer sequence that has been cloned into a DNA fragment between an adenovirus E3 (early region 3) leader sequence and an endosomal targeting sequence derived from the mouse major histocompatibility complex class II gene H2-DM. The endosomal targeting sequence is in directing the messenger RNA (mRNA) transcript to the endoplasmic reticulum for protein synthesis and secretion. The simian virus 40 (SV40) polyadenylation (PolyA) sequence on both the activation and responder plasmids stabilizes the respective mRNA transcripts. 
